… rivaroxaban to warfarin for treatment of NVAF in patients with a BMI >40 kg/m 2 . This study
identified patients with obesity by … When comparing rivaroxaban and warfarin, the composite …

… impact of obesity on this compound. This includes data obtained from both healthy obese
volunteers and obese patients with various CVD conditions enrolled in rivaroxaban clinical …

… of the DOAC rivaroxaban is not altered in patients with high … associated with rivaroxaban
in obese patientsCitation 23 , … of major bleeding) of rivaroxaban as compared to warfarin in …

… VTE patients with obesity who received rivaroxaban versus … rivaroxaban is safe and effective
versus warfarin, and associated with lower medical costs among VTE patients with obesity…

… The findings of our study add to previously published evidence of rivaroxaban use in obesity.
The PK/PD properties of rivaroxaban in patients with elevated body weight were studied by …

… Morbidly obese VTE patients receiving rivaroxaban had similar risks of recurrent VTE and
major bleeding versus warfarin. Rivaroxaban treatment yielded significantly less HRU and …

… The results of this study indicate that AF patients with morbid obesity initiating rivaroxaban
or warfarin had similar risks of ischemic stroke/systemic embolism and major bleeding in …

… demonstrating that patients with a morbidly obese BMI receiving rivaroxaban therapy are at
a … of literature on rivaroxaban prescribing trends, efficacy, and safety in obese population. …

… The impact of obesity on stroke outcomes in patients with AF … novel oral anticoagulant
rivaroxaban in obese patients has not … , and obese patients with AF treated with rivaroxaban and …

… However, given the single-center, retrospective nature of this study and the fact that
rivaroxaban has only recently been used in obese patients, we were unable to meet this condition, …